三元基因(837344) - 2023 Q1 - 季度财报

Financial Performance - Operating revenue for Q1 2023 was ¥34,376,162.80, reflecting a growth of 15.79% from ¥29,687,302.57 in Q1 2022[9] - Net profit attributable to shareholders decreased by 47.64% to ¥1,755,211.84 from ¥3,351,979.41 in the same period last year[9] - Total operating revenue for Q1 2023 reached ¥34,376,162.80, an increase from ¥29,687,302.57 in Q1 2022, representing a growth of approximately 15.7%[44] - Total operating costs for Q1 2023 were ¥32,475,766.48, up from ¥26,403,718.80 in Q1 2022, indicating an increase of about 22.5%[45] - Net profit for Q1 2023 was ¥1,755,211.84, a decrease from ¥3,351,979.41 in Q1 2022, reflecting a decline of approximately 47.6%[46] - Basic earnings per share for Q1 2023 were ¥0.01, down from ¥0.03 in Q1 2022[46] - Operating profit decreased to ¥2,301,716.04 from ¥3,951,638.70, a decline of about 41.8% compared to the previous year[49] - Net profit fell to ¥1,944,087.48 from ¥3,321,937.41, reflecting a decrease of approximately 41.3% year-over-year[50] - Basic and diluted earnings per share decreased to ¥0.02 from ¥0.03, a reduction of 33.3%[50] - Total comprehensive income amounted to ¥1,944,087.48, down from ¥3,321,937.41, indicating a decrease of about 41.3% year-over-year[50] Assets and Liabilities - Total assets as of March 31, 2023, reached ¥1,091,009,008.52, an increase of 16.89% compared to ¥933,400,392.16 at the end of 2022[9] - The company’s total liabilities to assets ratio increased to 47.05% from 38.42% year-over-year[9] - The company's total liabilities as of March 31, 2023, were ¥513,272,354.36, compared to ¥358,586,812.34 at the end of 2022[38] - The company's short-term borrowings increased to ¥26,531,524.32 as of March 31, 2023, from ¥13,831,518.24 at the end of 2022[37] - Total liabilities increased to ¥510,904,300.77 from ¥356,294,927.75, representing a rise of approximately 43.2%[42] - Current assets totaled ¥356,202,806.54, up from ¥347,954,594.37, showing a growth of about 2.1%[42] - Non-current assets increased to ¥753,699,534.73 from ¥604,226,423.90, indicating a growth of approximately 24.7%[42] - Long-term borrowings increased to ¥261,366,262.09 from ¥197,765,198.13, representing a growth of approximately 32.2%[42] Cash Flow - The net cash flow from operating activities was negative at -¥11,418,275.87, a decline of 180.53% compared to ¥14,178,778.03 in Q1 2022[10] - Cash flow from operating activities showed a net outflow of ¥11,418,275.87, compared to a net inflow of ¥14,178,778.03 in the same period last year[51] - Cash flow from investing activities resulted in a net outflow of ¥108,461,515.10, significantly higher than the outflow of ¥41,277,062.39 in the previous year[52] - Cash flow from financing activities generated a net inflow of ¥74,976,977.25, contrasting with a net outflow of ¥1,233,195.61 in the same period last year[52] - The ending cash and cash equivalents balance decreased to ¥180,526,369.49 from ¥225,429,183.21 at the end of 2022[36] - The ending cash and cash equivalents balance decreased to $175,181,373.76 from $244,282,490.73[55] - The company experienced a net decrease in cash and cash equivalents of -$41,841,821.74 compared to -$28,713,615.61 previously[55] Investments and R&D - The balance of construction in progress increased by 51.18% to ¥13,701.34 million, driven by the development of an intelligent R&D and production base for gene engineering drugs[11] - Investment activities saw a cash outflow increase of 162.76%, totaling ¥6,718.45 million, primarily for various R&D projects[17] - R&D expenses increased to ¥2,518,540.70 from ¥2,123,768.92, representing a growth of approximately 18.6% year-over-year[49] - The company is advancing its Phase III clinical trials for human interferon α1b nebulized inhalation treatment for pediatric RSV pneumonia, having completed work at 33 clinical research centers[32] - For the Phase III clinical trial of human interferon α1b for COVID-19 pneumonia, the company has added 8 new clinical research centers and received ethical approval for 9 centers, bringing the total to 15[32] - The company has completed the enrollment and follow-up of 19 cases for the Phase II/III adaptive clinical trial of a new PEG-integrated interferon mutant injection for hepatitis B[32] Shareholder Information - The total number of unrestricted shares is 113,560,796, representing 93.23% of the total share capital[21] - The total share capital is 121,810,000 shares, with 6,837 common shareholders[21] - The largest shareholder, Beijing Southeast Pharmaceutical Investment Holding Co., Ltd., holds 46,907,925 shares, accounting for 38.51% of the total shares[22] - The total number of restricted shares is 8,249,204, representing 6.77% of the total share capital[21] Compliance and Governance - The company has strictly adhered to commitments made during its public offering process, with no violations reported[30] - The company has not engaged in any litigation, arbitration, or external guarantees during the reporting period[27] - The stock option grant results for the 2022 stock incentive plan have been completed and announced[28] Construction and Development - The company has completed the construction of the main structure of its new gene engineering drug production and R&D base, which is part of a key project in Beijing[31] - The company has initiated the installation of purification and engineering equipment in its production workshop and R&D center[31] - The company has initiated civil construction for wastewater treatment and security facilities at its new site[31] Financial Expenses - Financial expenses rose by 44.91% due to increased interest expenses from short-term loans[16] - The company reported a significant increase in financial expenses, with interest expenses rising to ¥193,042.65 from ¥89,195.61, an increase of approximately 116.5%[49]